Please login to the form below

Not currently logged in
PMLiVE Top Pharma List


Revenue 2017


The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Herceptin was produced by Roche.

FDA panel backs Avastin and Herceptin biosimilars

FDA panel backs Avastin and Herceptin biosimilars A decision from the US regulator is expected in September. A US FDA advisory committee gave its blessing to two biosimilar versions of Roche's cancer antibodies Avastin and Herceptin yesterday, ... Meanwhile, sales of HER2-positive breast cancer therapy

Standing out in a crowd

Standing out in a crowd Celltrion’s Herceptin biosimilar - branded as Herzuma, it was submitted to the EMA for approval in November last year. ... versions of MabThera and Herceptin.

NICE relents on Kadcyla after Roche pricing negotiations

NICE relents on Kadcyla after Roche pricing negotiations older HER2-targeting drug Herceptin (trastuzumab) with capecitabine that has latterly become the standard treatment for advanced HER2-positive breast cancer.

Reactivating drug research programmes

Reactivating drug research programmes However, as drugs like Herceptin have shown, as long as there is a high degree of efficacy in a small group of patients, such treatments can still be commercially viable.

Roche trumpets APHINITY data, but did it hit the mark?

Roche trumpets APHINITY data, but did it hit the mark? One year of adjuvant therapy with Perjeta plus Herceptin and chemotherapy can cost upwards of $150, 000, roughly twice the cost of Herceptin alone. ... A large chunk of Perjeta's $5bn sales forecast has been attributed to adjuvant use alongside Herceptin

[ Previous 5 results ] 10 11 12 13 14 15 16 17 18 19 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs


Add my company
Bedrock Group

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

DEMAND DIVERSITY REPORT 02: Why is the LGBTQ+ community facing poorer health outcomes due to COVID-19?
We’re all aware that clinical trials have been discussed more widely since the COVID-19 pandemic. While that’s a great thing for raising awareness of clinical trials in general, it’s also...
CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...